Citius Pharmaceuticals (CTXR) Q3 2026 earnings summary

Executive summary

• Commercial launch of LYMPHIR in the U.S. began in December 2025, with expanding institutional adoption and initial shipments to Europe in April 2026.

• Achieved $7.1 million in revenue for the nine months ended June 30, 2026, driven by commercial sales of LYMPHIR.

• Expanded commercial and medical affairs teams to 29 professionals by August 2026, supporting nationwide deployment and engagement with treatment centers.

• LYMPHIR available in 44 leading oncology institutions, with significant growth in institutional orders and broad payer coverage.

• Advanced clinical programs for LYMPHIR in combination therapies, showing promising early results in gynecologic malignancies and DLBCL.

Financial highlights

• Revenue for the three and nine months ended June 30, 2026 was $1.49 million and $7.1 million, respectively, compared to zero in the prior year.

• Gross profit margins were approximately 67% for the quarter and 77% for the nine months.

• Net loss for the quarter was $11.9 million, up from $9.2 million year-over-year; net loss for the nine months was $49.4 million, up from $31.0 million.

• General and administrative expenses rose to $38.3 million for the nine months, reflecting a $19.7 million contract cancellation charge and launch costs.

• Cash and cash equivalents were $17.0 million at June 30, 2026, with negative working capital of $8.3 million.

Outlook and guidance

• Management expects continued revenue growth as LYMPHIR gains market acceptance and expands internationally.

• Available cash is expected to fund operations through November 2026; additional capital will be required thereafter.

• Ongoing engagement with the FDA for late-stage pipeline assets Mino-Lok and Halo-Lido.